Title for MeetingAbstracts
Alphabetical listing of titles
Durable clinical anti-HIV-1 activity (60 weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV) suppression to "less than 1 copy/ml" (OD=background) by Amplicor as a predictor of virologic treatment response [DMP 266-003, cohort IV].
Durable clinical anti-HIV-1 activity (72 weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV) [DMP 266-003, Cohort IV].
Durable community intervention on awareness against HIV/AIDS AJED's experience in Senegal.
Durable cure for tuberculosis: evaluation of KRM-1648 in a murine model of M. tuberculosis (MTB).
Durable HIV suppression and tolerability with efavirenz (EFV) + indinavir (IDV): results at 132 weeks (study 003-cohort IV).
Durable Long-Term Immune Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Plasmid Cytokine-Augmented DNA Vaccination.
Durable suppression of virus replication with saquinavir in combination with ritonavir and double nucleoside inhibitor therapy.
Durable suppression to less than 200 copies/ml in patients with HIV-1 viral loads greater than 100,000 using the four-drug combination of stavudine, lamivudine, saquinavir, and ritonavir.
Durable viral suppression on EFV-based HAART: 168 weeks of follow-up.
Duralex.
Duration and costs of hospitalization in patients with pancreatic cancer.
Duration in and pattern of utilization under a children health insurance program.
Duration of Antibiotic Therapy for Cholangitis after Successful Endoscopic Drainage of the Biliary Tract.
Duration of antibody (AB) levels after 3 doses of pneumococcal conjugate vaccine (PCV) in HIV+ and HIV- children less than 2 years of age.
Duration of antifungal treatment and development of delayed complications in patients with candidemia.
Duration of antiretroviral regimens, rate of treatment switching and cumulative exposure to antiretroviral agents.
Duration of antiretroviral use in pregnancy and vertical transmission of HIV in Rio de Janeiro, Brazil.
Duration of Colonization with Epidemic and Non-Epidemic Strains of Vancomycin-Resistant Enterococcus faecium.
Duration of effect of nevirapine (NVP), a cross-trial analysis of three controlled studies.
Duration of Efficacy after Primary Immunisation with Biken Acellular Pertussis Vaccine.
Duration of estrogen use and risk of breast cancer.
Duration of Fever During Treatment of Bacterial Meningitis.
Duration of nevirapine (NVP) postpartum exposure in women who received single dose NVP during labor in addition to standard zidovudine (ZDV) prophylaxis for the prevention of mother-to-child transmission of HIV-1 in Thailand.
Duration of Pleconaril (PLC) Effect on Cytochrome P450 3A (CYP3A) Activity Measured by the Biomarker Oral Midazolam (MDZ).
Duration of proleukin IL-2 therapy is more important than total dose in achieving CD4 expansion.
Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from fifteen prospective cohort studies.
Duration of survival in AIDS patients.
Duration of the antibody positive/ antigen positive phase of HIV infection.
Duration of the survival benefit of zidovudine in HIV infection.
Duration of treatment and reasons for changing in a cohort of patients in Brazil.